More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals

 
• By Bridget Silverman

Sponsors of established products like Amgen's Kyprolis and Blincyto and Bristol's Sprycel work to bulk up labeling with new indications while FDA reviews at least six novel agents for blood cancers.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment

More from Approvals

More from Product Reviews